Valuation: Nuvectra Corporation

Market Cap 1.7M 1.47M 1.38M 1.26M 2.37M 162M 2.41M 16.26M 6.35M 81.17M 6.38M 6.24M 271M P/E 2017
-1.84x
P/E 2018 -5.02x
Enterprise Value -53.46M -46.34M -43.44M -39.61M -74.53M -5.1B -75.72M -511M -200M -2.55B -201M -196M -8.52B EV / Sales 2017
2.58x
EV / Sales 2018 4.76x
Free-Float
96.76%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer 78 30/01/2019
Compliance Officer 51 31/12/2014
Director TitleAgeSince
Director/Board Member 67 29/02/2016
Director/Board Member 78 29/02/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+16.67% - - 268K
-0.16%+3.33%-13.83%+5.00% 193B
+0.36%+4.73%-0.76%+9.77% 116B
-0.44%-3.52%+4.85%+64.78% 59.16B
+0.32%+3.92%+38.42%+65.14% 55.75B
-0.38%+2.88%-6.69%-35.62% 49.57B
-0.66%+7.63%+14.08%-21.20% 34.52B
+0.10%+1.26% - - 31.22B
+0.10%-2.07%+40.83%-13.29% 24.36B
+1.98%+12.62%-2.80%+25.91% 24.25B
Average +0.17%+5.35%+9.26%+12.56% 58.73B
Weighted average by Cap. +0.10%+3.53%+1.37%+13.25%

Financials

2017 2018
Net sales 31.84M 27.6M 25.87M 23.59M 44.38M 3.04B 45.09M 305M 119M 1.52B 120M 117M 5.07B 48.83M 42.33M 39.68M 36.18M 68.07M 4.66B 69.16M 467M 182M 2.33B 183M 179M 7.78B
Net income -44.6M -38.66M -36.24M -33.04M -62.18M -4.26B -63.17M -427M -167M -2.13B -167M -164M -7.11B -48.13M -41.72M -39.11M -35.66M -67.1M -4.59B -68.17M -460M -180M -2.3B -181M -177M -7.67B
Net Debt -1.49M -1.29M -1.21M -1.1M -2.08M -142M -2.11M -14.26M -5.57M -71.18M -5.59M -5.47M -237M -55.16M -47.81M -44.82M -40.87M -76.89M -5.26B -78.13M -528M -206M -2.64B -207M -203M -8.79B
Logo Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Employees
-
  1. Stock Market
  2. Stocks
  3. NVTRQ Stock